Back

Common AAV gene therapy vectors show indiscriminate transduction of living human brain cell types

McGinnis, J.; Ortiz-Guzman, J.; Guevara, M. C.; Mallannagari, S.; Belfort, B. D.; Bao, S.; Srivastava, S.; Morkas, M.; Ji, E.; Addison, A.; Tantry, E.; Chen, S.; Wang, Y.; Chen, Z.; Katlowitz, K. A.; Lange, J. J.; Blessing, M.; Mohila, C.; Ljungberg, M. C.; Aldave, G.; Jalali, A.; Patel, A.; Sheth, S.; Weiner, H. L.; Gopinath, S.; Rao, G.; Serin-Harmanci, A.; Curry, D.; Arenkiel, B.

2024-11-15 bioengineering
10.1101/2024.11.14.623624 bioRxiv
Show abstract

The development of cell-type-specific gene therapy vectors for treating neurological diseases holds great promise, but has relied on animal models with limited translational utility. We have adapted an ex vivo organotypic model to evaluate adeno-associated virus (AAV) transduction properties in living slices of human brain tissue. Using fluorescent reporter expression and single-nucleus RNA sequencing, we found that common AAV vectors show broad transduction of normal cell types, with protein expression most apparent in astrocytes; this work introduces a pipeline for identifying and optimizing AAV gene therapy vectors in human brain samples.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.